• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受嵌合抗原受体 T 细胞治疗的血液恶性肿瘤癌症患者的患者报告结局:系统评价。

Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.

机构信息

Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Department of Stem Cell and Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

Transplant Cell Ther. 2021 May;27(5):390.e1-390.e7. doi: 10.1016/j.jtct.2021.01.003. Epub 2021 Jan 7.

DOI:10.1016/j.jtct.2021.01.003
PMID:33965176
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8110951/
Abstract

Databases were searched to identify studies published over the past 10 years that addressed the utility of patient-reported outcomes (PROs) in patients receiving chimeric antigen receptor (CAR) T cell therapy in patients with hematological malignancies. Among 280 records, three articles covering 206 patients were eligible. The data were prospectively collected at multiple time points. The compliance rates were 70% to 94%. There was an inverse relationship between fatigue and social function among adults. The quality of life (QoL) improvement and ability to complete PROs were linked to disease status. About 40% of adults reported at least some cognitive difficulties, with a detrimental impact on mental and physical health status. In adults, the most commonly reported cognitive impairment was memory difficulties. Depression was associated with cognitive difficulties. Younger adults were at higher risk of long-term poor mental health, anxiety, and depression. For pediatric and adolescent patients, emotional dysfunction improves over time. QoL status improved over time; yet, severe cytokine release syndrome and neurotoxicity caused delayed improvement. Information regarding whether the PROs were integrated into medical records and clinical guidelines is lacking. Utilizing PROs in patients on CAR T cell therapy seems feasible and informative. Studies utilizing larger sample sizes and using validated PRO tools at different time points remain unmet needs.

摘要

检索数据库,以确定过去 10 年中发表的研究,这些研究探讨了患者报告结局(PROs)在接受嵌合抗原受体(CAR)T 细胞治疗血液系统恶性肿瘤患者中的应用。在 280 篇记录中,有 3 篇涵盖 206 例患者的文章符合条件。数据是在多个时间点前瞻性收集的。依从率为 70%至 94%。成年人的疲劳和社会功能之间呈负相关。生活质量(QoL)的改善和完成 PROs 的能力与疾病状态有关。约 40%的成年人报告至少存在一些认知困难,对身心健康状况有不利影响。在成年人中,最常见的认知障碍是记忆力困难。抑郁与认知困难有关。年轻成年人患长期精神健康不良、焦虑和抑郁的风险更高。对于儿科和青少年患者,情绪功能障碍随时间改善。QoL 状况随时间改善;然而,严重的细胞因子释放综合征和神经毒性导致改善延迟。关于 PROs 是否被纳入病历和临床指南的信息尚不清楚。在接受 CAR T 细胞治疗的患者中使用 PROs似乎是可行且有益的。仍需要使用更大的样本量和在不同时间点使用经过验证的 PRO 工具进行研究。

相似文献

1
Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.接受嵌合抗原受体 T 细胞治疗的血液恶性肿瘤癌症患者的患者报告结局:系统评价。
Transplant Cell Ther. 2021 May;27(5):390.e1-390.e7. doi: 10.1016/j.jtct.2021.01.003. Epub 2021 Jan 7.
2
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
3
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.嵌合抗原受体 T 细胞治疗后免疫效应细胞相关神经毒性综合征的临床表现、危险因素和结局:系统评价。
Transplant Cell Ther. 2022 Jun;28(6):294-302. doi: 10.1016/j.jtct.2022.03.006. Epub 2022 Mar 11.
4
Music interventions for improving psychological and physical outcomes in people with cancer.音乐干预对改善癌症患者心理和生理结局的影响。
Cochrane Database Syst Rev. 2021 Oct 12;10(10):CD006911. doi: 10.1002/14651858.CD006911.pub4.
5
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
6
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.
7
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
8
Exercise interventions and patient beliefs for people with hip, knee or hip and knee osteoarthritis: a mixed methods review.髋、膝或髋膝骨关节炎患者的运动干预和患者信念:一项混合方法综述
Cochrane Database Syst Rev. 2018 Apr 17;4(4):CD010842. doi: 10.1002/14651858.CD010842.pub2.
9
Reminiscence therapy for dementia.痴呆症的回忆疗法
Cochrane Database Syst Rev. 2018 Mar 1;3(3):CD001120. doi: 10.1002/14651858.CD001120.pub3.
10
Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.成人癫痫新药的临床疗效、耐受性及成本效益:一项系统评价与经济学评估
Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. doi: 10.3310/hta9150.

引用本文的文献

1
Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study.用于CAR T细胞疗法患者的电子患者报告结局(ePRO)系统的指标选择:一项改良的德尔菲共识研究
EClinicalMedicine. 2025 May 28;84:103256. doi: 10.1016/j.eclinm.2025.103256. eCollection 2025 Jun.
2
Long-term neurocognitive effects of chimeric antigen receptor T-cell therapy: Integrating assessments into nursing practice.嵌合抗原受体T细胞疗法的长期神经认知效应:将评估纳入护理实践
Can Oncol Nurs J. 2024 Jul 1;34(3):293-303. doi: 10.5737/23688076343293. eCollection 2024 Summer.
3

本文引用的文献

1
Advances in CAR T Therapy for Hematologic Malignancies.嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤的研究进展。
Pharmacotherapy. 2020 Aug;40(8):741-755. doi: 10.1002/phar.2414. Epub 2020 Jun 3.
2
CAR-T treatment for hematological malignancies.嵌合抗原受体T细胞(CAR-T)疗法治疗血液系统恶性肿瘤。
J Investig Med. 2020 Jun;68(5):956-964. doi: 10.1136/jim-2020-001290. Epub 2020 Mar 21.
3
Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.嵌合抗原受体T细胞疗法治疗B细胞血液系统恶性肿瘤:关键临床试验数据更新
Promoting patient-centered care in CAR-T therapy for hematologic malignancy: a qualitative meta-synthesis.
促进 CAR-T 疗法治疗血液恶性肿瘤中的以患者为中心的护理:定性元分析。
Support Care Cancer. 2024 Aug 16;32(9):591. doi: 10.1007/s00520-024-08799-3.
4
Nursing care for chimeric antigen receptor T cell therapy survivors: A literature review.嵌合抗原受体T细胞疗法幸存者的护理:文献综述
Asia Pac J Oncol Nurs. 2024 Apr 22;11(6):100495. doi: 10.1016/j.apjon.2024.100495. eCollection 2024 Jun.
5
Remission after CAR T-cell therapy: Do lymphoma patients recover a normal life?CAR-T细胞疗法后的缓解:淋巴瘤患者能恢复正常生活吗?
Hemasphere. 2024 May 27;8(5):e72. doi: 10.1002/hem3.72. eCollection 2024 May.
6
Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress.接受嵌合抗原受体T细胞疗法治疗的血液系统恶性肿瘤患者的健康相关生活质量:综述与当前进展
Haematologica. 2024 Aug 1;109(8):2401-2419. doi: 10.3324/haematol.2022.282363.
7
Patient-reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic review.用于癌症接受过继细胞治疗(ACT)的患者的患者报告结局(PRO)工具:系统评价。
Syst Rev. 2023 Sep 30;12(1):183. doi: 10.1186/s13643-023-02337-8.
8
Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.嵌合抗原受体 T 细胞的早期和晚期毒性。
Hematol Oncol Clin North Am. 2023 Dec;37(6):1169-1188. doi: 10.1016/j.hoc.2023.05.010. Epub 2023 Jun 21.
9
The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic.远程医疗在改善 CAR-T 细胞疗法项目中的作用:从 COVID-19 大流行中吸取的教训。
Support Care Cancer. 2023 May 25;31(6):350. doi: 10.1007/s00520-023-07811-6.
10
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap.细胞疗法试验中的患者报告结局:关注差距。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-006082.
Pharmaceutics. 2020 Feb 24;12(2):194. doi: 10.3390/pharmaceutics12020194.
4
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.复发/难治性弥漫性大B细胞淋巴瘤患者接受替沙格宁治疗后的长期生活质量报告
Blood Adv. 2020 Feb 25;4(4):629-637. doi: 10.1182/bloodadvances.2019001026.
5
Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.抗 CD19 CAR T 细胞疗法治疗 B 细胞非霍奇金淋巴瘤。
Transfus Med Rev. 2020 Jan;34(1):29-33. doi: 10.1016/j.tmrv.2019.08.003. Epub 2019 Aug 29.
6
CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.嵌合抗原受体 T 细胞疗法在血液系统恶性肿瘤中的应用:征途漫漫。
Clin Pharmacol Ther. 2020 Jan;107(1):112-122. doi: 10.1002/cpt.1674. Epub 2019 Nov 25.
7
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.儿童和青少年复发或难治性 B 细胞急性淋巴细胞白血病患者接受 tisagenlecleucel 输注后的患者报告生活质量:一项全球性、单臂、2 期临床试验。
Lancet Oncol. 2019 Dec;20(12):1710-1718. doi: 10.1016/S1470-2045(19)30493-0. Epub 2019 Oct 9.
8
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.嵌合抗原受体 T 细胞治疗后长期生存者的患者报告神经精神结局。
Biol Blood Marrow Transplant. 2020 Jan;26(1):34-43. doi: 10.1016/j.bbmt.2019.09.037. Epub 2019 Oct 9.
9
Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.嵌合抗原受体 T 细胞疗法的患者报告结局:挑战与机遇。
Biol Blood Marrow Transplant. 2019 May;25(5):e155-e162. doi: 10.1016/j.bbmt.2018.11.025. Epub 2018 Nov 28.
10
Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.嵌合抗原受体修饰(CAR-)T 细胞治疗后细胞因子释放综合征和神经毒性。
Br J Haematol. 2018 Nov;183(3):364-374. doi: 10.1111/bjh.15644. Epub 2018 Nov 8.